Ponesimod
- Generic Name
- Ponesimod
- Brand Names
- Ponvory
- Drug Type
- Small Molecule
- Chemical Formula
- C23H25ClN2O4S
- CAS Number
- 854107-55-4
- Unique Ingredient Identifier
- 5G7AKV2MKP
- Background
Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than fingolimod. Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.
Ponesimod was granted FDA approval on 18 March 2021.
- Indication
Ponesimod is indicated to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Actelion
- Target Recruit Count
- 877
- Registration Number
- NCT03232073
- Locations
- 🇫🇷
Hopital Nord Laennec - CHU NANTES, Nantes Cedex 1, France
🇵🇱NEURO MEDIC Janusz Zbrojkiewicz Poradnia Wielospecjalistyczna, Katowice, Poland
🇵🇱Centrum Opieki Zdrowotnej Orkan Med, Ksawerow, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.